<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77702">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02093962</url>
  </required_header>
  <id_info>
    <org_study_id>TH-CR-415</org_study_id>
    <nct_id>NCT02093962</nct_id>
  </id_info>
  <brief_title>Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer</brief_title>
  <official_title>A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Threshold Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EMD Serono</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Threshold Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether TH-302 in combination with pemetrexed is
      safe and effective in the treatment of non-squamous non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TH-302 is designed to target the hypoxic regions of tumors which are generally located
      distant from tumor vessels. Pemetrexed has poor tissue penetration and targets the regions
      of tumors that are located in proximity to the tumor vessels. The presence of hypoxia in
      solid tumors is associated with a more malignant phenotype and resistance to chemotherapy.
      The hypoxia-activated prodrug, TH-302, is designed to selectively target the hypoxic
      microenvironment. There is evidence supporting the presence of hypoxia in NSCLC lesions
      based on a hypoxia PET study. Combining pemetrexed with TH-302 may enable the targeting of
      both the normoxic and hypoxic regions of NSCLC lesions.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    At the interim analysis, the futility boundary was not met and the study was stopped due to
    insufficient efficacy.
  </why_stopped>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>To assess the efficacy of pemetrexed in combination with TH-302 as determined by overall survival in patients with advanced non-squamous NSCLC in the second-line chemotherapy setting compared with pemetrexed in combination with placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events in patients treated with TH-302 in combination with pemetrexed vs pemetrexed alone</measure>
    <time_frame>2 years</time_frame>
    <description>To assess the safety of TH-302 in combination with pemetrexed compared with placebo and pemetrexed in this setting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population PK of TH-302 in patients treated with TH-302 for measures including clearance and volume of distribution</measure>
    <time_frame>2 years</time_frame>
    <description>To investigate the pharmacokinetics of TH-302 in this patient population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate anti-tumor activity as measured by progression-free survival and response rate in patients treated with TH-302 in combination with pemetrexed vs pemetrexed alone</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate the anti-tumor activity of pemetrexed in combination with TH-302 compared with pemetrexed in combination with placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">265</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>TH-302 and pemetrexed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TH-302 in combination with pemetrexed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and pemetrexed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Matching placebo in combination with pemetrexed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TH-302 combination with pemetrexed</intervention_name>
    <description>400 mg/m2 of TH-302 will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle.
Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after TH-302 administration.</description>
    <arm_group_label>TH-302 and pemetrexed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matched placebo in combination with pemetrexed</intervention_name>
    <description>Matched placebo will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle.
Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after placebo administration.</description>
    <arm_group_label>Placebo and pemetrexed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women ≥ 18 years of age.

          -  Histologically or cytologically confirmed stage IIIB or IV NSCLC with non-squamous
             histology

          -  Recurrent or progressive disease after one prior platinum-based non-pemetrexed
             chemotherapy treatment for advanced disease with or without maintenance

          -  Neoadjuvant/adjuvant cytotoxic chemotherapy initiated &lt; 12 months prior to study
             randomization will be counted as one prior treatment

          -  Neoadjuvant/adjuvant cytotoxic chemotherapy initiated ≥ 12 months prior to study
             randomization will not be counted as one prior chemotherapy treatment

          -  Use of targeted agents (e.g., monoclonal antibodies or kinase inhibitors) will not be
             counted as a prior chemotherapy treatment

          -  Patients with known EGFR-activating mutations or ALK rearrangements should have
             received treatment with a targeted kinase inhibitor (e.g., erlotinib, crizotinib) and
             no longer be considered as a candidate for such treatment

          -  Measurable disease according to RECIST 1.1

          -  ECOG performance status 0-1

          -  Resolution to Grade ≤ 1 Adverse Events, of all clinically significant toxic effects
             of prior therapy

          -  Adequate hematologic, hepatic, cardiac, and renal function

          -  Female patients of childbearing potential must have a negative serum or urine
             pregnancy test, whichever is considered standard by the institution

        Exclusion Criteria:

          -  Diagnosis of small cell carcinoma of the lung, squamous cell carcinoma of the lung or
             NSCLC NOS

          -  Prior therapy with pemetrexed

          -  Inability or unwillingness to take folic acid, vitamin B12 supplementation or
             corticosteroids

          -  Inability to discontinue non-steroidal anti-inflammatory drugs for 5 days (long
             half-life) or for 2 days (short half-life, if CrCL &lt;80 mL/min) before pemetrexed
             dosing and until 2 days after pemetrexed dosing

          -  Leptomeningeal disease or any untreated or symptomatic brain metastases, unless the
             following criteria are met:

               -  brain metastases are stable and have been previously treated with either
                  whole-brain radiotherapy or gamma-knife surgery

               -  steroids are currently not required and more than 14 days since last steroid
                  treatment

          -  Symptomatic pleural effusion (&gt; CTCAE Grade 1 dyspnea) that is not amenable to
             drainage

          -  Treatment with other systemic anticancer therapy within 4 weeks prior to the first
             dose of study medication

          -  Treatment with full field radiation therapy within 4 weeks or limited field radiation
             therapy within 2 weeks prior to the first dose of study medication

          -  Major surgery within 4 weeks or minor surgery within 2 weeks prior the first dose of
             study medication

          -  Elective or a planned major surgery while on study treatment

          -  Radiation therapy to greater than 25% of the bone marrow

          -  Clinically significant active infection (e.g. tuberculosis, viral hepatitis, HIV)

          -  Any other serious uncontrolled medical disorders or psychological conditions that may
             interfere with study conduct

          -  Concurrent active malignancy other than adequately treated basal cell or squamous
             cell carcinoma of the skin or pre-invasive carcinoma of the cervix.

          -  Pregnant or breast feeding

          -  Patients who are taking medications that prolong QT interval and have a risk of
             Torsades de Pointes (Appendix F) or who have a history of long QT syndrome

          -  Patients who are taking medications that are strong inducers or inhibitors of CYP3A4
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tillman Pearce, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Threshold Pharmaceuticals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan Goldman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA-Dept of Medicine a Div of Hem/Onc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Cancer and Research Centers</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Cancer Center</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Cancer Center Associates</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA-Department of Medicine a Division of Hem/Onc</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarcoma Oncology Research Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Eastern Colorado Healthcare System</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health Services</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Specialists of North Florida - CBO</name>
      <address>
        <city>Jacksonville Beach</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMPM Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinical Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy Ann Arbor Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefire-Einstein Center for Cancer Care</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Alliance</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durham VA Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>W.G. (Bill) Hefner VA Medical Center</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DORN VA Medical Center</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Care Institute at Regional Health</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates in Oncology &amp; Hematology</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Antonio Military Medical Center</name>
      <address>
        <city>Fort Sam Houston</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Consultants</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Millennium Oncology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fpr Belvoir Community Hospital</name>
      <address>
        <city>Fort Belvoir</city>
        <state>Virginia</state>
        <zip>22060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Na Bulovce, Department of Pneumology and Thoracic Surgery</name>
      <address>
        <city>Liben</city>
        <zip>18081</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Univesity Hospital in Prague, Clinic of Oncology</name>
      <address>
        <city>Prague</city>
        <zip>12800</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomayer Hospital, Clinic of Pneumology</name>
      <address>
        <city>Praha 4</city>
        <zip>140 59</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Hospital T. Bta, Department of Pneumology</name>
      <address>
        <city>Zlin</city>
        <zip>76275</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Fachkliniken Munchen-Gaunting</name>
      <address>
        <city>Gauting</city>
        <state>Bavaria</state>
        <zip>82131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marien Hospital Herne</name>
      <address>
        <city>Herne</city>
        <state>North Rhine-Westphalia</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin;</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt Höchst GmbH</name>
      <address>
        <city>Frankfurt</city>
        <zip>65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lungen Clinic Grosshandsdorf GmbH</name>
      <address>
        <city>Grosshansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Schleswig-Holstein</name>
      <address>
        <city>Lubeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum München - Klinikum Bogenhausen</name>
      <address>
        <city>München</city>
        <zip>81925</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm; Zentrum für Innere Medizin</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IASO General, Oncology Unit</name>
      <address>
        <city>Athens</city>
        <zip>15562</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Attikon University General Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medical Oncology</name>
      <address>
        <city>Crete</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Patras, Oncology Unit</name>
      <address>
        <city>Patras</city>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Koranyi National Institute of TBC and Pulmonology, 14th Dept of Pulmonology</name>
      <address>
        <city>Budapest</city>
        <zip>1121</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Koranyi National Institute of TBC and Pulmonology, 6th Department of Pulmonology</name>
      <address>
        <city>Budapest</city>
        <zip>1121</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Koranyi National Institute of TBC and Pulmonology, 8th Department of Pulmonology</name>
      <address>
        <city>Budapest</city>
        <zip>1121</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Debrecen, Medical and Health Science Center, Department of Pulmonology</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Csongrad County Hospital of Chest Diseases</name>
      <address>
        <city>Deszk</city>
        <zip>6772</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hetenyi Geza Hospital, Department of Oncology</name>
      <address>
        <city>Szolnok</city>
        <zip>5004</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Mater Salutis&quot; Hospital - Operative Unit of Oncology</name>
      <address>
        <city>Verona</city>
        <state>Legnago</state>
        <zip>37045</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U.S. Luigi GonzagaUniversity Hospital</name>
      <address>
        <city>Orbassano</city>
        <state>Torino</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Bellaria &quot;Carlo Alberto Pizzardi&quot; - Operative Unit of Oncology</name>
      <address>
        <city>Bologna</city>
        <zip>40139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Azienda Ospedallera Universitaria San Martino-IST-Istituto Nazionale per la Ricerca sul Cancro</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>European Institute of Oncology (IEO) - Medical Care Unit</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S. Gerardo Hospital - Complex Structure of Medical Oncology</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico della Seconda Universita di Napoli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Pisa, Department of Cardothoracic Surgery, Operative unit of Pneumology</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Santa Maria degli Angeli&quot; - Hospital - Complex Operative Unit of Oncology</name>
      <address>
        <city>Pordenone</city>
        <zip>33170</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Camillo-Forlanini Hospital - U.O.C. Pneumologia Oncologica 1</name>
      <address>
        <city>Rome</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med-Polonia Sp. z o.o.</name>
      <address>
        <city>Poznan</city>
        <zip>60693</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L. Rydygier Provencial Hospitals in Torun, Dept. of Tumors Chemotherapy</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Institute of Oncology in Warsaw</name>
      <address>
        <city>Warsaw</city>
        <zip>02781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Centre &quot;Sf. Nectarie&quot;</name>
      <address>
        <city>Craiova</city>
        <state>Dolj County</state>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pro. Dr. Alex Trestioreanu Institute of Oncology</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Dr. Ioan Chiricuta Institute of Oncology</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Oncology Center under the Ministry of Healthcare of Tatarstan Republic</name>
      <address>
        <city>Kazan</city>
        <state>Republic of Tatarstan</state>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Oncology Research Center n.a. N.N. Blokhin under the Russian Academy of Medical Sciences</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blokhin Russian Oncology Research Center</name>
      <address>
        <city>Moscow</city>
        <zip>15478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution: Nizhny Novgorod Regional Oncology Center</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603081</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg Clinical Center for Applied Special Medical Services (Oncology)</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg 1st State Medical University n.a.I.P. Pavlov under the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197101</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Oncology Center, Oncology Department (Thoracic Oncology)</name>
      <address>
        <city>St. Petersburg</city>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General University Hospital Gregorio Maranon, Dept. of Oncology</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jimenez Diaz Foundation</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Virgen de Valme</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Peset University Hospital, Dept. of Oncology</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe, Servicio de Oncologia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 1, 2016</lastchanged_date>
  <firstreceived_date>March 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TH-302</keyword>
  <keyword>TH-CR-415</keyword>
  <keyword>Pemetrexed</keyword>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>Lung cancer</keyword>
  <keyword>Evofosfamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Phosphoramide Mustards</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
